Literature DB >> 19284307

Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition.

Corine Demanga Galamo1, Ali Jafarshad, Catherine Blanc, Pierre Druilhe.   

Abstract

We investigated whether anti-merozoite surface protein-1 (MSP1) block 2 antibodies mediate the monocyte-dependent antibody-mediated cellular inhibition (ADCI) of Plasmodium falciparum. This study was performed because soluble molecules have been shown to trigger ADCI and because MSP1 block 2 is released following processing and is the target of cytophilic IgG3 responses in exposed populations. We assessed human anti-MSP1 block 2 antibodies against 4 P. falciparum strains that carry the 3 main block 2 sequence alleles. These antibodies were able to inhibit in vitro growth of P. falciparum only in cooperation with human monocytes, whereas no direct inhibition was observed. However, the ADCI effect was strictly allele specific. Our findings highlight a new mechanism involving MSP1 in the protection against malaria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284307     DOI: 10.1086/597426

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Authors:  Maryam Imam; Yengkhom Sangeeta Devi; Akhilesh K Verma; Virander Singh Chauhan
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

3.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

4.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

5.  Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.

Authors:  Anja Jäschke; Boubacar Coulibaly; Edmond J Remarque; Hermann Bujard; Christian Epp
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

Review 6.  Repetitive sequences in malaria parasite proteins.

Authors:  Heledd M Davies; Stephanie D Nofal; Emilia J McLaughlin; Andrew R Osborne
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

7.  A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.

Authors:  Kevin K A Tetteh; David J Conway
Journal:  Vaccine       Date:  2011-08-04       Impact factor: 3.641

8.  Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4.

Authors:  Sandra P Chang; Alexander K K Kayatani; Zilka I Terrientes; Socrates Herrera; Rose G F Leke; Diane W Taylor
Journal:  Malar J       Date:  2010-01-13       Impact factor: 2.979

9.  Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites.

Authors:  Alfred Amambua-Ngwa; Kevin K A Tetteh; Magnus Manske; Natalia Gomez-Escobar; Lindsay B Stewart; M Elizabeth Deerhake; Ian H Cheeseman; Christopher I Newbold; Anthony A Holder; Ellen Knuepfer; Omar Janha; Muminatou Jallow; Susana Campino; Bronwyn Macinnis; Dominic P Kwiatkowski; David J Conway
Journal:  PLoS Genet       Date:  2012-11-01       Impact factor: 5.917

10.  Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Authors:  Nekoye Otsyula; Evelina Angov; Elke Bergmann-Leitner; Margaret Koech; Farhat Khan; Jason Bennett; Lucas Otieno; James Cummings; Ben Andagalu; Donna Tosh; John Waitumbi; Nancy Richie; Meng Shi; Lori Miller; Walter Otieno; Godfrey Allan Otieno; Lisa Ware; Brent House; Olivier Godeaux; Marie-Claude Dubois; Bernhards Ogutu; W Ripley Ballou; Lorraine Soisson; Carter Diggs; Joe Cohen; Mark Polhemus; D Gray Heppner; Christian F Ockenhouse; Michele D Spring
Journal:  Malar J       Date:  2013-01-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.